The overall goal of this study was to develop a computational framework to quantify hip, knee, and ankle joint forces during exoskeletal-assisted walking (EAW) in the ReWalk P6.0, an FDA-approved lower-extremity exoskeleton. The first objective was to quantify hip, knee, and ankle joint forces during unassisted walking and compare the results to existing in vivo and simulation data. The second objective was to compare hip, knee, and ankle joint forces from four different approaches to simulate human-robot interactions during EAW. We recorded the three-dimensional motion of one able-bodied participant during unassisted walking and EAW, with simultaneous measurements of (i) marker trajectories, (ii) ground reaction forces, (iii) electromyography, and (iv) exoskeleton encoder data. We developed a subject-specific virtual simulator in OpenSim to reproduce unassisted walking and EAW. Next, we utilized OpenSim’s extension, OpenSim Moco, to determine the joint reaction forces at the hips, knees, and ankles during unassisted walking and EAW. The computed peak hip, knee, and ankle joint compressive forces during unassisted walking were 3.42-3.82 body weight (BW), 3.10-3.48 BW, and 4.97-5.83 BW, respectively; these joint forces were comparable to prior in vivo and simulation results. The four approaches to simulate human-robot interactions during EAW resulted in peak compressive forces ranging from 2.98-4.66 BW, 2.82-5.83 BW, and 3.39-3.79 BW at the hip, knee, and ankle joints, respectively. This computational framework provides a low-risk and cost-effective technique to quantify the loading of the long bones and assess fracture risk during EAW in patients with severe bone loss in the lower extremities.

The authors have declared no competing interest.

This work was supported by the Department of Veterans Affairs under Grant VA RR&D # 1 I01 RX003561-01A2; and the National Science Foundation Graduate Research Fellowship Program under application #1000346414 (Fellow ID: 2022346414).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board at New Jersey Institute of Technology approved this study. The approval number is 2008001531. Written consent was obtained.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data files will be available from the Figshare database only after acceptance of the manuscript for publication.